Single Dose Study of ALZ-801 Prototype Tablets
NCT04585347
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer Disease
Interventions
DRUG:
ALZ-801 170 mg Fasting
DRUG:
ALZ-801 205 mg Fasting
DRUG:
ALZ-801 205 mg After Food
DRUG:
ALZ-801 342 mg Fasting
Sponsor
Alzheon Inc.
Collaborators
[object Object]